Boehringer Taking Over Actimis In Structured Buyout
This article was originally published in The Pink Sheet Daily
Deal worth up to $515 million brings Phase I asthma therapy.
You may also be interested in...
The pharma pledges $50 million to the California firm’s new seventh round, which it anticipates closing more than eight years after its sixth. For GSK, it’s the latest tie-up with a VC firm as part of a regional investment strategy.
Astellas Outlicenses Products To California Startup, Considers Expanding Model To More Of Its Portfolio
TOKYO - Astellas Pharma Inc. is trying out a new model, out-licensing three compounds to a startup created specifically to support the development of the products while Astellas retains options to buy back the products. The Japanese pharma is reducing costs for non-priority therapeutic targets, and if successful, may repeat the model for other compounds in its pipeline
Astellas' Out-Licensing Deal With Cardeus Could Be Model For Development Outsourcing Of More Of Its Portfolio
Astellas has looked to outsource some development programs with "satellite companies" and believes the solution may rest with small startups.